IBRX
Another lawsuit, because biotech never sleeps
ImmunityBio is back in the hot seat. A securities class action says investors who bought shares between January 19 and March 24 got burned after the FDA flagged claims tied to Anktiva, the company’s lead biologic.
The core beef here is simple: did the company oversell what Anktiva could do? According to the complaint, executive chairman and Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong made comments in a podcast and TV ad that suggested the drug could do a lot more than its FDA-approved use in bladder cancer.
Why investors should care
This isn’t just legal drama for legal-drama’s sake. The FDA reportedly said the materials were “false or misleading,” and that kind of language is basically a flashing neon sign for stock volatility. The shares already dropped more than 21% on March 24, so this lawsuit adds another layer of uncertainty around the name.
The takeaway
For ImmunityBio, the question isn’t whether the PR team can spin this — it’s whether investors now have another reason to demand answers. In biotech, hype can be rocket fuel. But if regulators think the fuel is shaky, the landing gets bumpy fast.
Big picture: when the FDA starts calling promotional claims misleading, the market tends to stop laughing and start suing.